Department of Urology, Mayo Clinic, Rochester, MN 55905, USA.
BJU Int. 2011 Sep;108(6):816-9. doi: 10.1111/j.1464-410X.2010.09946.x. Epub 2010 Dec 16.
• To assess the risk of metachronous renal cell carcinoma (RCC) and benign renal tumours after surgical treatment of primary renal oncocytoma.
• Patients treated for primary renal oncocytoma between 1970 and 2007 were identified. Tumours were reviewed by a urological pathologist and patients were followed for subsequent renal tumours.
• Of 424 patients with a median follow up of 7.1 year, 17 (4.0%) patients were diagnosed with a metachronous renal tumour at a median of 3.0 years (range 0.3-16 years). Of the 17 metachronous tumours, eight were oncocytoma, four were RCC and five were not resected or biopsied. • Eleven metachronous tumours occurred after solitary unilateral oncocytoma, five occurred after multifocal unilateral oncocytoma, and one occurred after multifocal bilateral oncocytoma. • Estimated 10-year tumour-free and RCC tumour-free survival was 94.8% and 98.7%, respectively. Patients with primary multifocal oncocytoma were at higher risk of metachronous tumour (hazard ratio 4.0; P = 0.007). Initial oncocytoma size (hazard ratio 1.1; P = 0.11) was not highly associated with risk of tumour recurrence.
• To our knowledge, we report the largest cohort of oncocytoma after surgical management. Metachronous renal neoplasm in a patient with previous oncocytoma is more likely to be benign compared with patients who present with a renal tumour for the first time. Multifocal primary oncocytoma is associated with metachronous renal tumours. • Overall, the risk of metachronous RCC in a patient with an oncocytoma is similar to that of the general population, which does not support the use of routine cross-sectioning imaging surveillance.
评估肾嗜酸细胞瘤(oncocytoma)手术后发生异时性肾细胞癌(RCC)和良性肾肿瘤的风险。
回顾性分析 1970 年至 2007 年间接受手术治疗的肾嗜酸细胞瘤患者。由泌尿科病理学家对肿瘤进行复查,并对患者进行随访以发现后续的肾肿瘤。
424 例患者的中位随访时间为 7.1 年,其中 17 例(4.0%)患者在中位 3.0 年后(范围 0.3-16 年)被诊断为异时性肾肿瘤。在 17 例异时性肿瘤中,8 例为嗜酸细胞瘤,4 例为 RCC,5 例未切除或活检。11 例异时性肿瘤发生在单侧单发嗜酸细胞瘤之后,5 例发生在单侧多灶性嗜酸细胞瘤之后,1 例发生在双侧多灶性嗜酸细胞瘤之后。估计 10 年无肿瘤和无 RCC 肿瘤的生存率分别为 94.8%和 98.7%。患有原发性多灶性嗜酸细胞瘤的患者发生异时性肿瘤的风险更高(风险比 4.0;P = 0.007)。初始嗜酸细胞瘤大小(风险比 1.1;P = 0.11)与肿瘤复发风险无显著相关性。
据我们所知,这是手术后肾嗜酸细胞瘤最大的队列研究。与首次出现肾肿瘤的患者相比,先前患有嗜酸细胞瘤的患者发生异时性肾新生物更可能是良性的。多灶性原发性嗜酸细胞瘤与异时性肾肿瘤相关。总的来说,患有嗜酸细胞瘤的患者发生异时性 RCC 的风险与普通人群相似,这并不支持常规进行横断面成像监测。